Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07306390 | Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)(DIAMOND) | not yet recruiting | — | 1,200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| 1 |
| Jun 5, 2026 |
| clinicaltrials |
| NCT05167994 | Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）(SPARE-01) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma(RAIRI-NPC) | recruiting | Phase 3 | 651 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07618078 | Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC | recruiting | — | 900 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02688036 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC | completed | Phase 3 | 860 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612098 | Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma(SPARE-04) | not yet recruiting | Phase 2 | 274 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03583580 | Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer | active not recruiting | N/A | 537 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07596524 | Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy | not yet recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07395479 | A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening | recruiting | Early Phase 1 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06761417 | A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults | recruiting | Phase 2 | 49 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06926751 | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors | recruiting | Phase 2 | 132 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07043894 | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients | recruiting | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07249879 | This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. | recruiting | Phase 1 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 204 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07561463 | Sacituzumab Tirumotecan for Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07551414 | Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI | not yet recruiting | Phase 2 | 38 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06233981 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07530549 | A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy | not yet recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT07531563 | Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy(C-Head-002) | not yet recruiting | N/A | 504 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT07514897 | Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring | recruiting | — | 250 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05749289 | Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression | recruiting | Phase 2 / Phase 3 | 400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06048146 | A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis | completed | N/A | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06509022 | Longitudinal Study on the Evolution Trend and Influencing Factors of Postoperative Reflux of Esophageal Cancer Based on PEPTEST Technique | enrolling by invitation | — | 138 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07480863 | Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL | active not recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07507058 | Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma | not yet recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Apr 2, 2026 | clinicaltrials |
| NCT07478809 | A Retrospective Real-World Study Based on RATIONALE-307 | recruiting | — | 109 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07480837 | Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma | active not recruiting | — | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07435701 | Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites | recruiting | Phase 1 / Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476378 | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies(Archonc-001) | not yet recruiting | N/A | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476677 | Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer(ANDARP) | not yet recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07203729 | The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis | recruiting | Phase 2 | 184 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07461727 | An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases | not yet recruiting | Phase 1 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07120282 | Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC | recruiting | Phase 2 | 108 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06820320 | Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy | completed | Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07454941 | Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics | enrolling by invitation | — | 4,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07443397 | Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. | recruiting | Phase 3 | 134 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05888402 | Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC(InTRist) | active not recruiting | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07033819 | Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | recruiting | Phase 2 | 48 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07110103 | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC(JACKPOT38) | recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07440888 | The Factors Influencing the Success of Redo Surgery and Anal Function for Anastomosis Failure or Local Tumor Recurrence | completed | — | 143 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07440901 | Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy | not yet recruiting | — | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | not yet recruiting | Phase 2 | 82 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07352280 | Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer | recruiting | — | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07413601 | Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 78 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07409766 | A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors | not yet recruiting | Early Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07396116 | Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)(FUSION-02) | not yet recruiting | N/A | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07405047 | Fractionated Stereotactic Radiotherapy for Limited Small Volume Brain Metastases | completed | N/A | 33 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials